Bristol-Myers Squibb Company, commonly referred to as BMS, is a leading global biopharmaceutical firm headquartered in the United States. Founded in 1887, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative medicines in oncology, immunology, and cardiovascular disease. BMS is renowned for its groundbreaking therapies, such as Opdivo and Eliquis, which have transformed treatment paradigms and improved patient outcomes. The company’s commitment to research and development has positioned it as a key player in the pharmaceutical industry, consistently achieving significant milestones, including numerous FDA approvals and recognitions for its contributions to healthcare. With a robust pipeline and a dedication to addressing unmet medical needs, Bristol-Myers Squibb continues to solidify its market position as a pioneer in biopharmaceutical innovation.
How does Bristol-Myers Squibb's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bristol-Myers Squibb's score of 71 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Bristol-Myers Squibb (BMS) reported significant carbon emissions, totalling approximately 2,117,929,000 kg CO2e globally. This includes 208,535,000 kg CO2e from Scope 1 (direct emissions) and 158,447,000 kg CO2e from Scope 2 (indirect emissions related to energy use). Notably, Scope 3 emissions accounted for a substantial 1,750,947,000 kg CO2e, primarily from purchased goods and services. BMS has set ambitious climate commitments, aiming for net-zero emissions across all scopes by 2050. The company has established near-term targets to reduce absolute Scope 1 and 2 GHG emissions by 54.6% by 2033, using 2022 as the baseline year. Additionally, BMS plans to reduce Scope 3 emissions from fuel and energy-related activities by the same percentage within the same timeframe. By 2040, BMS aims to achieve net neutrality in both Scope 1 and Scope 2 emissions. The company is also committed to ensuring that 75% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2028. Furthermore, BMS has pledged to reduce absolute Scope 1 and 2 GHG emissions by 90% and Scope 3 emissions by 90% by 2050, relative to the 2022 baseline. BMS's climate strategy aligns with industry standards and reflects a proactive approach to addressing climate change, demonstrating leadership in the pharmaceutical sector.
Access structured emissions data, company-specific emission factors, and source documents
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|
Scope 1 | 210,540,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 150,790,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | 69,630,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bristol-Myers Squibb is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.